<p>|Nonsteroidal antiinflammatory drugs|Any at therapeutic dosing (ibuprofen, naproxen, tolmetin, indomethacin, meloxicam, nabumetone, diclofenac, piroxicam, etodolac, celecoxib)|
|---|---|
|Conventional synthetic disease-modifying antirheumatic drugs|Methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, calcineurin inhibitors (cyclosporin A, tacrolimus)|
|Biologic disease-modifying antirheumatic drugs|Tumor necrosis factor inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol); other biologic response modifiers (abatacept, tocilizumab, anakinra, canakinumab)|
|Glucocorticoids|Oral (any); intravenous (any); intraarticular (triamcinolone acetonide, triamcinolone hexacetonide)|</p>

<h1>Table 2. Strength of recommendations and quality of supporting evidence*</h1>